Simcere Pharmaceutical Group Limited

As of December 31, 2025, Simcere Pharmaceutical Group Limited carries a market capitalization of 31.07B, placing it among publicly traded companies globally. Its enterprise value stands at 28.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Simcere Pharmaceutical Group Limited's next confirmed earnings release is scheduled for March 25, 2027.

As of December 31, 2025, Simcere Pharmaceutical Group Limited has 2.60B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Simcere Pharmaceutical Group Limited maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Simcere Pharmaceutical Group Limited's stock has declined approximately 19.10% over the past 52 weeks. The 50-day moving average sits at 11.44, while the 200-day moving average is 11.68.

As of December 31, 2025, Simcere Pharmaceutical Group Limited holds 3.98B in cash and equivalents against 1.32B in total debt, resulting in a net debt position of -2.73B. Total book value stands at 10.47B, with working capital of 4.50B providing operational flexibility.